New horizons in particle therapy systems

Farr, J; Flanz, J.; Gerbershagen, Alexander; Moyers, Michael F.

doi:10.1002/mp.13193

Cited by 32 publications

(50 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Although this report focuses on the clinical commissioning of IMPT, it is not intended to describe IMPT systems in detail as such information is available elsewhere. 2,12 Instead, the intent is to systematically review the technical commissioning needs of a new proton therapy system, including ancillary devices such as image guidance (IG) equipment and the TMS. Very basic systems, such as room lasers are not covered, and advanced functionality, such as treatment planning techniques, motion management, gating, and target tracking, are left to future reports.…”

Section: Tdsmentioning

confidence: 99%

Clinical commissioning of intensity‐modulated proton therapy systems: Report of AAPM Task Group 185

Farr¹,

Moyers²,

Allgower

et al. 2020

Medical Physics

Self Cite

View full text Add to dashboard Cite

Proton therapy is an expanding radiotherapy modality in the United States and worldwide. With the number of proton therapy centers treating patients increasing, so does the need for consistent, high-quality clinical commissioning practices. Clinical commissioning encompasses the entire proton therapy system's multiple components, including the treatment delivery system, the patient positioning system, and the image-guided radiotherapy components. Also included in the commissioning process are the x-ray computed tomography scanner calibration for proton stopping power, the radiotherapy treatment planning system, and corresponding portions of the treatment management system. This commissioning report focuses exclusively on intensitymodulated scanning systems, presenting details of how to perform the commissioning of the proton therapy and ancillary systems, including the required proton beam measurements, treatment planning system dose modeling, and the equipment needed.

show abstract

Section: Tdsmentioning

confidence: 99%

Clinical commissioning of intensity‐modulated proton therapy systems: Report of AAPM Task Group 185

Farr¹,

Moyers²,

Allgower

et al. 2020

Medical Physics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The intensity upgrade at SIS18 can be exploited to test RIB therapy in the same Cave M (Figure 5) where the pilot project was performed. The project Biomedical Applications of Radioactive ion Beams (BARB) (www.gsi.de/BARB) aims at testing 10,11 C and 14,15 O for simultaneous treatment and imaging at FAIR, with the goal of reaching sub-mm precision in range verification and to demonstrate the potential of RIB therapy in an animal model. BARB is funded by EU within the 2019 ERC Advanced Grant call and is a 5-year project starting in late 2020.…”

Section: Barbmentioning

confidence: 99%

“…The first reason is the higher cost of the CPT facilities [10], especially the expensive heavy ion centers. Even if the cost is still much higher for particle therapy centers compared to linacs for X-rays, it is declining, mostly thanks to superconductive technologies now employed for the construction of the accelerators (cyclotrons, synchro-cyclotrons, or synchrotrons) [11,12]. However, CPT is also limited in what should be the main advantage, i.e., the high precision made possible by the Bragg peak.…”

Section: Introductionmentioning

confidence: 99%

Radioactive Beams in Particle Therapy: Past, Present, and Future

Durante

Parodi

2020

Front. Phys.

View full text Add to dashboard Cite

Heavy ion therapy can deliver high doses with high precision. However, image guidance is needed to reduce range uncertainty. Radioactive ions are potentially ideal projectiles for radiotherapy because their decay can be used to visualize the beam. Positron-emitting ions that can be visualized with PET imaging were already studied for therapy application during the pilot therapy project at the Lawrence Berkeley Laboratory, and later within the EULIMA EU project, the GSI therapy trial in Germany, MEDICIS at CERN, and at HIMAC in Japan. The results show that radioactive ion beams provide a large improvement in image quality and signal-to-noise ratio compared to stable ions. The main hindrance toward a clinical use of radioactive ions is their challenging production and the low intensities of the beams. New research projects are ongoing in Europe and Japan to assess the advantages of radioactive ion beams for therapy, to develop new detectors, and to build sources of radioactive ions for medical synchrotrons.

show abstract

“…The higher costs of proton therapy with respect to conventional radiotherapy also limit its applicability [3]. There have been efforts from research institutions and industrial partners to reduce the size of proton accelerators [22], [23] as well as the overall price of facilities [24], [25]. Likewise, there is a trend in the field of proton range verification to reduce both the cost and size of currently available prototypes by proposing innovative detection approaches.…”

Section: Introductionmentioning

confidence: 99%

Compact Method for Proton Range Verification Based on Coaxial Prompt Gamma-Ray Monitoring: A Theoretical Study

Hueso-González

Bortfeld

2020

IEEE Trans. Radiat. Plasma Med. Sci.

View full text Add to dashboard Cite

Range uncertainties in proton therapy hamper treatment precision. Prompt gamma-rays were suggested 16 years ago for real-time range verification, and have already shown promising results in clinical studies with collimated cameras. Simultaneously, alternative imaging concepts without collimation are investigated to reduce the footprint and price of current prototypes. In this manuscript, a compact range verification method is presented. It monitors prompt gamma-rays with a single scintillation detector positioned coaxially to the beam and behind the patient. Thanks to the solid angle effect, proton range deviations can be derived from changes in the number of gammarays detected per proton, provided that the number of incident protons is well known. A theoretical background is formulated and the requirements for a future proof-of-principle experiment are identified. The potential benefits and disadvantages of the method are discussed, and the prospects and potential obstacles for its use during patient treatments are assessed. The final milestone is to monitor proton range differences in clinical cases with a statistical precision of 1 mm, a material cost of 25000 USD and a weight below 10 kg. This technique could facilitate the widespread application of in vivo range verification in proton therapy and eventually the improvement of treatment quality.

show abstract

New horizons in particle therapy systems

Cited by 32 publications

References 61 publications

Clinical commissioning of intensity‐modulated proton therapy systems: Report of AAPM Task Group 185

Clinical commissioning of intensity‐modulated proton therapy systems: Report of AAPM Task Group 185

Radioactive Beams in Particle Therapy: Past, Present, and Future

Compact Method for Proton Range Verification Based on Coaxial Prompt Gamma-Ray Monitoring: A Theoretical Study

Contact Info

Product

Resources

About